When the numbers don’t add up…
Last week I wrote about the emerging evidence on the consequences for public health of fiscal austerity in Europe.
Pricing
European Parliament 'Transparency Directive' vote
EFPIA welcomes Commission decision for a policy strategy agenda to strengthen the competitiveness of the pharmaceutical industry
Need for concrete measures at national level to help stimulate innovation and ensure access for all European patients to modern medicines
10.10.2012, Brussels: EFPIA welcomes today’s Commission Communication on industrial policy as an important step to seeking to secure the competitiveness of the EU pharmaceutical industry and protect access to medicines for all of Europe’s citizens.
Launch of online resource for challenging drug patents by MSF
On Tuesday 2nd October MSF launched an online resource to help civil society groups and patient groups in developing countries to challenge unwarranted drug patents through patent oppositions.
Life Science Frontiers: Bridging the gap between science and healthcare
22 November 2012 - Uppsala, Sweden
Organised by The Economist Group, Life Sciences Frontiers will take place in Uppsala Congress and Conference Centre in Uppsala, Sweden.
The event will explore radical and innovative ways of bringing together science and healthcare to address the challenge of creating high-quality patient-centric care at an affordable price.
Patients' W.A.I.T. Indicator - Report 2010
The latest edition shows that, depending on the patients' country of residence, doctors would be able to prescribe between 39% and 86% of the new medicines with a valid EU marketing authorisation granted between 1 January 2007 and 31 December 2009. For those new medicines that doctors can prescribe under the national healthcare provisions, average time elapsing between the date of EU market authorisation and the "accessibility" date in 14 European countries will vary from 88 to 392 days.
Market Access Delays
President of EFPIA calls for pharma innovation to be a key part of a European growth strategy
Europe must make choices to remain a home for biomedical innovation.
Transparency Directive (COM (2012)0084) - (29 May 2012)
The Commission proposal for a revised Transparency Directive (“the Proposal”) is an important and necessary step towards more efficient decision-making by member states in pricing and reimbursement (P&R) of medicines. At a time when countries across the EU are seeking improved management of their healthcare systems, it is essential that the procedural aspects of P&R decision-making are brought towards similar standards of quality and efficiency.
Weekly Press Review -- 19-25 June, 2012
Check out what we are reading this week.
